Drug details

Susvimo (ranibizumab injection)

type of Ophthalmics, VEGF Inhibitors

Susvimo (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• feeling like something is in your eye,
• decreased vision,
• dry or irritated eyes,
• severe eye pain,
• redness in the white of the eye,
• extreme sensitivity to bright light,
• swelling of the eyelid,
• floaters in the eye,
• sudden flashes of light,
• shadows in the vision field,
• implant dislocation,
• cloudy vision,
• lines or dark dots in your vision,
• difficulty closing your eye,
• postoperative decrease in visual acuity,
• air bubbles causing improper filling of the implant, and
• deflection of the implant

The following drugs are related to Susvimo, either as a replacement or used together:

• Eylea (aflibercept)
• Avastin (bevacizumab)
• Beovu (brolucizumab-dbll for intravitreal injection)
• Vabysmo (faricimab-svoa injection)
• Lucentis (ranibizumab injection)
• Syfovre (pegcetacoplan injection, for intravitreal use)